

# CITATION REPORT

List of articles citing

## Therapeutic drug monitoring of voriconazole

DOI: 10.1097/ftd.ob013e31817b1a95

Therapeutic Drug Monitoring, 2008, 30, 403-11.

**Source:** <https://exaly.com/paper-pdf/44929767/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
111	Therapeutic drug monitoring of voriconazole in a child with invasive aspergillosis requiring extracorporeal membrane oxygenation. <i>Therapeutic Drug Monitoring</i> , <b>2008</b> , 30, 643-6	3.2	39
110	Role of therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections. <b>2009</b> , 62, 469-82		8
109	Accelerated metabolism of voriconazole and its partial reversal by cimetidine. <b>2009</b> , 53, 1712-4		32
108	Hypersusceptibility to azole antifungals in a clinical isolate of <i>Candida glabrata</i> with reduced aerobic growth. <b>2009</b> , 53, 3034-41		17
107	Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation. <b>2009</b> , 63, 767-70		96
106	Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts. <b>2009</b> , 29, 1306-25		16
105	High voriconazole trough levels in relation to hepatic function: how to adjust the dosage?. <b>2009</b> , 67, 262-3		20
104	Dose tolerability of chronically inhaled voriconazole solution in rodents. <b>2009</b> , 379, 25-31		16
103	Herb-drug interactions with St John's wort ( <i>Hypericum perforatum</i> ): an update on clinical observations. <b>2009</b> , 11, 710-27		169
102	Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution. <b>2009</b> , 72, 199-205		43
101	Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. <b>2009</b> , 48, 1441-58		300
100	Hallucinations during voriconazole therapy: who is at higher risk and could benefit from therapeutic drug monitoring?. <i>Therapeutic Drug Monitoring</i> , <b>2009</b> , 31, 135-6	3.2	2
99	Validated liquid chromatography-tandem mass spectroscopy method for the simultaneous quantification of four antimycotic agents in human serum. <i>Therapeutic Drug Monitoring</i> , <b>2010</b> , 32, 453-7	3.2	18
98	Clinician ordering practices for voriconazole therapeutic drug monitoring: experiences of a referral laboratory. <i>Therapeutic Drug Monitoring</i> , <b>2010</b> , 32, 661-4	3.2	15
97	Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS. <b>2010</b> , 878, 39-44		77
96	Determination of voriconazole in human serum and plasma by micellar electrokinetic chromatography. <b>2010</b> , 53, 1313-8		13
95	Comparison of Relationship between Dosage and Serum Concentration of Voriconazole in Adult and Pediatric Patients. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , <b>2010</b> , 36, 213-219	0.1	1

94	Oral voriconazole dose in children: one size does not fit all. <b>2010</b> , 51, 870; author reply 871	8
93	Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. <b>2010</b> , 54, 3225-32	61
92	Intravenous voriconazole after toxic oral administration. <b>2010</b> , 54, 2741-2	9
91	Q fever, free amoeba, and air conditioning. <b>2010</b> , 51, 869-70	2
90	Utilisation, efficacy and safety of voriconazole: prospective, non-interventional study on treatment of IFIs in clinical practice. <b>2011</b> , 27, 335-42	
89	Detection and investigation of invasive mould disease. <b>2011</b> , 66 Suppl 1, i15-24	93
88	Safety and pharmacokinetics of a single 1500-mg dose of famciclovir in adolescents with recurrent herpes labialis. <b>2011</b> , 30, 525-8	7
87	Trends in hospitalization for empyema in Alaska Native children younger than 10 years of age. <b>2011</b> , 30, 528-30	9
86	No efficacy of prednisolone in acute wheezing associated with human bocavirus infection. <b>2011</b> , 30, 521-3	14
85	Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy. <b>2011</b> , 30, 535-7	17
84	Occurrence of acute otitis media during colds in children younger than four years. <b>2011</b> , 30, 518-20	8
83	Pharmacokinetics of voriconazole during continuous venovenous hemofiltration. <i>Therapeutic Drug Monitoring</i> , <b>2011</b> , 33, 372; author reply 372	3.2
82	Therapeutic drug monitoring for drugs used in the treatment of substance-related disorders: literature review using a therapeutic drug monitoring appropriateness rating scale. <i>Therapeutic Drug Monitoring</i> , <b>2011</b> , 33, 561-72	3.2 20
81	Pharmacokinetics of polymyxin B in an infant with multidrug-resistant <i>Klebsiella pneumoniae</i> bacteremia. <b>2011</b> , 30, 537-9	2
80	Impact of therapeutic drug monitoring of voriconazole in a pediatric population. <b>2011</b> , 30, 533-4	38
79	Catheter-associated aspergillosis of the chest wall following allogeneic hematopoietic stem cell transplantation. <b>2011</b> , 13, 182-5	6
78	Voriconazole toxicity related to polymorphisms in CYP2C19. <b>2011</b> , 41, 364-5	6
77	Comparison and evaluation of a novel bioassay and high-performance liquid chromatography for the clinical measurement of serum voriconazole concentrations. <b>2011</b> , 54, e421-8	8

76	Clinical importance of the CYP2C19*17 variant allele for voriconazole. <b>2011</b> , 71, 137-8	16
75	Pharmacotherapy of Invasive Fungal Infections with Voriconazole. <b>2011</b> , 3, 83-95	
74	Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. <b>2012</b> , 56, 2371-7	100
73	Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study. <b>2012</b> , 67, 700-6	64
72	Therapeutic drug monitoring of voriconazole in children. <i>Therapeutic Drug Monitoring</i> , <b>2012</b> , 34, 77-84	3.2 29
71	In vitro pharmacokinetic/pharmacodynamic modeling of voriconazole activity against <i>Aspergillus</i> species in a new in vitro dynamic model. <b>2012</b> , 56, 5321-7	17
70	Fast and simple LC-MS/MS method for quantifying plasma voriconazole. <b>2012</b> , 413, 740-3	34
69	The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. <b>2012</b> , 55, 1080-7	276
68	ESCMID* guideline for the diagnosis and management of <i>Candida</i> diseases 2012: diagnostic procedures. <b>2012</b> , 18 Suppl 7, 9-18	239
67	Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. <b>2012</b> , 55, 381-90	154
66	How do I Adjust Antimicrobial Daily Dosage in Patients with MODS? A Pharmacist's Contribution. <b>2012</b> , 199-217	
65	An automated method for the simultaneous measurement of azole antifungal drugs in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry. <b>2012</b> , 404, 513-23	26
64	Risk factors for voriconazole hepatotoxicity at 12 weeks in lung transplant recipients. <b>2012</b> , 12, 1929-35	37
63	Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. <b>2013</b> , 19, 381-92	73
62	Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity. <b>2013</b> , 424, 119-22	40
61	Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis. <b>2013</b> , 60, 82-7	35
60	Determination of voriconazole serum concentration by bioassay, a valid method for therapeutic drug monitoring for clinical laboratories. <b>2013</b> , 57, 3437-40	9
59	Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. <b>2013</b> , 57, 235-40	55

58	Clinical Impact of Cytochrome P450 2C19 Genotype on the Treatment of Invasive Aspergillosis under Routine Therapeutic Drug Monitoring of Voriconazole in a Korean Population. <b>2013</b> , 45, 406-14	28
57	Setting Clinical MIC Breakpoints from a PK/PD Point of View: It Is the Dose That Matters. <b>2014</b> , 45-61	5
56	Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and <i>Aspergillus fumigatus</i> in an in vitro pharmacokinetic/pharmacodynamic model. <b>2014</b> , 69, 1611-9	23
55	ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: <i>Fusarium</i> spp., <i>Scedosporium</i> spp. and others. <b>2014</b> , 20 Suppl 3, 27-46	291
54	Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. <b>2014</b> , 69, 1162-76	404
53	[Pharmacology of the antifungals used in the treatment of aspergillosis]. <b>2014</b> , 31, 255-61	3
52	Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity. <b>2014</b> , 44, 183-93	59
51	Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis. <b>2014</b> , 58, 4727-36	17
50	Plasma fluoride level as a predictor of voriconazole-induced periostitis in patients with skeletal pain. <b>2014</b> , 59, 1237-45	56
49	Guías de recomendaciones sobre diagnóstico, tratamiento y prevención de infecciones en pacientes con cáncer 2013. <b>2014</b> , 46, 7-144	6
48	Five year results of an international proficiency testing programme for measurement of antifungal drug concentrations. <b>2014</b> , 69, 2988-94	23
47	Screening of the central nervous system in children with invasive pulmonary aspergillosis. <b>2014</b> , 4, 8-11	12
46	Drugs Active against Fungi, Pneumocystis, and Microsporidia. <b>2015</b> , 479-494.e4	7
45	Achieving target voriconazole concentrations more accurately in children and adolescents. <b>2015</b> , 59, 3090-7	48
44	The Clinical Significance of Voriconazole Therapeutic Drug Monitoring in Children With Invasive Fungal Infections. <b>2015</b> , 32, 557-67	16
43	Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole. <b>2015</b> , 9, 74-87	30
42	Gain-of-function single nucleotide variants of the CYP2C19 gene (CYP2C19*17) can identify subtherapeutic voriconazole concentrations in critically ill patients: a case series. <b>2015</b> , 41, 2013-4	5
41	Efficacy and cost-effectiveness of voriconazole prophylaxis for prevention of invasive aspergillosis in high-risk liver transplant recipients. <b>2016</b> , 22, 163-70	22

40	The Impact of Model-Misspecification on Model Based Personalised Dosing. <b>2016</b> , 18, 1244-1253			3
39	An Optimized Voriconazole Dosing Strategy to Achieve Therapeutic Serum Concentrations in Children Younger than 2 Years Old. <b>2016</b> , 36, 1102-1108			12
38	Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections. <b>2016</b> , 14, 731-46			13
37	Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics. <b>2017</b> , 83, 1954-1965			13
36	Biomarker Analysis of the Effects of Intranasally Dosed PC945, a Novel Antifungal Triazole, on <i>Aspergillus fumigatus</i> Infection in Immunocompromised Mice. <b>2017</b> , 61,			13
35	Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections. <b>2017</b> , 27, 190-196			27
34	Pharmacokinetics of a single dose of voriconazole administered orally with and without food to red-tailed hawks ( <i>Buteo jamaicensis</i> ). <b>2017</b> , 78, 433-439			9
33	Significance of monitoring plasma concentration of voriconazole in a patient with liver failure: A case report. <b>2017</b> , 96, e8039			6
32	Relationship Between the CYP2C19 Phenotype Using the Voriconazole-to-Voriconazole N-Oxide Plasma Concentration Ratio and Demographic and Clinical Characteristics of Japanese Patients With Different CYP2C19 Genotypes. <i>Therapeutic Drug Monitoring</i> , <b>2017</b> , 39, 514-521	3.2		15
31	Performance evaluation of enzyme immunoassay for voriconazole therapeutic drug monitoring with automated clinical chemistry analyzers. <b>2017</b> , 8, 86-94			6
30	Optimizing Single-Drug Antibacterial and Antifungal Therapy. <b>2017</b> , 157-179			1
29	and Efficacy of a Novel and Long-Acting Fungicidal Azole, PC1244, on <i>Aspergillus fumigatus</i> Infection. <b>2018</b> , 62,			12
28	Individualized Medication of Voriconazole: A Practice Guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. <i>Therapeutic Drug Monitoring</i> , <b>2018</b> , 40, 663-674	3.2		27
27	Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole. <b>2018</b> , 84, 1980-1988			22
26	Novel Treatment of Disseminated Coccidioidomycosis in a Dog with Voriconazole. <b>2018</b> , 2018, 1785748			1
25	Manual punch versus automated flow-through sample desorption for dried blood spot LC-MS/MS analysis of voriconazole. <b>2018</b> , 1089, 16-23			5
24	Risk factors associated with insufficient and potentially toxic voriconazole plasma concentrations: an observational study. <b>2019</b> , 31, 401-407			3
23	Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients. <b>2019</b> , 15, 881-895			35

22	Toxicity studies for the use of prodrug of voriconazole in rats. <b>2019</b> , 104, 8-13		3
21	High voriconazole target-site exposure after approved sequence dosing due to nonlinear pharmacokinetics assessed by long-term microdialysis. <i>European Journal of Pharmaceutical Sciences</i> , <b>2019</b> , 131, 218-229	5.1	6
20	Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients. <b>2019</b> , 57, 937-943		9
19	Pharmacokinetic/Pharmacodynamic Analysis of Voriconazole Against <i>Candida</i> spp. and <i>Aspergillus</i> spp. in Allogeneic Stem Cell Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 740-747	3.2	1
18	An Observational Study of the Efficacy and Safety of Voriconazole in a Real-Life Clinical Setting. <b>2019</b> , 31, 49-57		4
17	Effect of CYP2C19 polymorphism on the plasma voriconazole concentration and voriconazole-to-voriconazole-N-oxide concentration ratio in elderly patients. <b>2020</b> , 63, 1181		5
16	Administration and Dosing of Systemic Antifungal Agents in Pediatric Patients. <b>2020</b> , 22, 165-188		9
15	Tacrolimus Concentration after Letermovir Initiation in Hematopoietic Stem Cell Transplantation Recipients Receiving Voriconazole: A Retrospective, Observational Study. <b>2020</b> , 17, 859-864		5
14	Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling. <b>2021</b> , 60, 261-270		4
13	Influence of switching from intravenous to oral administration on serum voriconazole concentration. <b>2021</b> , 46, 780-785		1
12	Characterization of Therapeutic Drug Monitoring Practices of Voriconazole and Posaconazole at a Pediatric Hospital. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , <b>2021</b> , 26, 26-32	1.6	0
11	Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. <i>Lancet, The</i> , <b>2021</b> , 397, 499-509	4.0	38
10	Relationship between anti-fungal effects and lung exposure of PC945, a novel inhaled antifungal agent, in <i>Aspergillus fumigatus</i> infected mice: Pulmonary PK-PD analysis of anti-fungal PC945. <i>European Journal of Pharmaceutical Sciences</i> , <b>2021</b> , 163, 105878	5.1	0
9	Systemic Antifungal Agents. <b>2010</b> , 549-563		5
8	Therapeutic Drugs and Their Management. <b>2012</b> , 1057-1108		2
7	Factors Associated With Voriconazole Concentration in Pediatric Patients. <i>Therapeutic Drug Monitoring</i> , <b>2020</b> , 42, 866-871	3.2	1
6	Determination of saliva trough levels for monitoring voriconazole therapy in immunocompromised children and adults. <i>Therapeutic Drug Monitoring</i> , <b>2010</b> , 32, 194-9	3.2	10
5	Voriconazole monitoring in children with invasive fungal infections. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , <b>2015</b> , 20, 17-23	1.6	11

- 4 Hepatotoxicity of Voriconazole: A Retrospective Study. *Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)*, **2009**, 35, 579-584 0.1 1
- 3 Antifungal effects of PC945, a novel inhaled triazole, on *Candida albicans*-infected immunocompromised mice.
- 2 Lower prealbumin and higher CRP increased the risk of Voriconazole overexposure and adverse reactions. 0
- 1 Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. **2022**, 44, 1604-1623 1